Aptamer Group (APTA) Competitors GBX 0.38 0.00 (0.00%) As of 08:05 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock APTA vs. FUM, OKYO, AOR, SAR, POLB, AREC, RLM, NSCI, OPTI, and IXIShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Futura Medical (FUM), OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), Poolbeg Pharma (POLB), Arecor Therapeutics (AREC), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), and IXICO (IXI). These companies are all part of the "biotechnology" industry. Aptamer Group vs. Its Competitors Futura Medical OKYO Pharma AorTech International Sareum Poolbeg Pharma Arecor Therapeutics Realm Therapeutics NetScientific OptiBiotix Health IXICO Aptamer Group (LON:APTA) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk. Which has more volatility and risk, APTA or FUM? Aptamer Group has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Futura Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Does the media prefer APTA or FUM? In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Futura Medical'saverage media sentiment score. Company Overall Sentiment Aptamer Group Neutral Futura Medical Neutral Is APTA or FUM more profitable? Futura Medical has a net margin of -44.64% compared to Aptamer Group's net margin of -343.95%. Futura Medical's return on equity of -56.44% beat Aptamer Group's return on equity.Company Net Margins Return on Equity Return on Assets Aptamer Group-343.95% -205.63% -44.96% Futura Medical -44.64%-56.44%-26.59% Do institutionals and insiders believe in APTA or FUM? 11.7% of Aptamer Group shares are held by institutional investors. Comparatively, 35.7% of Futura Medical shares are held by institutional investors. 13.2% of Aptamer Group shares are held by company insiders. Comparatively, 32.1% of Futura Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has stronger valuation and earnings, APTA or FUM? Futura Medical has higher revenue and earnings than Aptamer Group. Futura Medical is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptamer Group£4.12M1.83-£14.17M-£0.71-0.53Futura Medical£8.68M2.64-£3.88M-£1.21-6.08 SummaryFutura Medical beats Aptamer Group on 9 of the 11 factors compared between the two stocks. Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£7.55M£123.89M£5.48B£2.95BDividend YieldN/A3.74%5.38%5.02%P/E Ratio-0.533.2826.21141.44Price / Sales1.833,653.26395.51214,272.26Price / CashN/A13.1936.4927.99Price / Book1.7843.047.914.60Net Income-£14.17M-£92.79M£3.15B£5.90B7 Day Performance10.47%0.25%0.77%0.84%1 Month Performance12.43%2.04%3.46%4.67%1 Year Performance-41.54%180.98%34.61%81.03% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 0.38flatN/A-40.6%£7.55M£4.12M-0.5337Gap DownFUMFutura MedicalN/AGBX 8.52+2.8%N/A-79.7%£26.54M£8.68M-7.0212Gap DownOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383SARSareumN/AGBX 14.50flatN/A-59.6%£18.12MN/A-3.433,211Gap UpPOLBPoolbeg PharmaN/AGBX 3.28+13.1%N/A-74.5%£16.86MN/A0.0012Positive NewsGap UpARECArecor TherapeuticsN/AGBX 42.30-2.8%N/A-62.5%£15.97M£6.04M-1.4910Gap DownRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/ANSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.45+0.7%N/A-28.1%£11.21M£590.01K-3.621Earnings ReportIXIIXICON/AGBX 10.78-2.0%N/A+47.9%£9.99M£11.50M-2.7989Gap Down Related Companies and Tools Related Companies Futura Medical Alternatives OKYO Pharma Alternatives AorTech International Alternatives Sareum Alternatives Poolbeg Pharma Alternatives Arecor Therapeutics Alternatives Realm Therapeutics Alternatives NetScientific Alternatives OptiBiotix Health Alternatives IXICO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:APTA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
